Get to know our clinical trials
Fosfomycin as an oral alternative therapy in the treatment of acute bacterial prostatitis caused by multidrug-resistant Escherichia coli
THE AIM OF THE STUDY IS TO EVALUATE THE EFFICACY OF SEQUENTIAL TREATMENT WITH ORAL FOSFOMYCIN IN PATIENTS DIAGNOSED WITH PROSTATITIS AFTER 2 TO 5 DAYS OF THERAPY WITH AN ANTIBIOTIC SUITABLE FOR THE MICROORGANISM ISOLATED PARENTERALLY, ALSO STUDYING THE PHARMACOKINETIC PARAMETERS OF ORAL FOSFOMYCIN, IN ORDER TO FIND AN EFFECTIVE AND SAFE TREATMENT REGIMEN THAT IMPROVES THE PATIENT'S QUALITY OF LIFE, REDUCING THE NUMBER OF DAYS OF HOSPITALIZATION AND AVOIDING SIDE EFFECTS
Technical Summary
- FOSFOMYCIN AS AN ORAL ALTERNATIVE THERAPY IN THE TREATMENT OF ACUTE BACTERIAL PROSTATITIS CAUSED BY MULTIDRUG-RESISTANT ESCHERICHIA COLI
- Code EudraCT: 2019-003792-19
- Protocol number: FOS-PROST-001
- Promoter: Fundación Miguel Servet
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.